| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 3.91 | 15.7% | 147.5% |
| Total Income | 3.91 | 15.7% | 147.5% |
| Expenditure | 38.65 | 19.7% | 95.4% |
| PBT | — | ||
| Net Profit | -29.94 | 24.0% | 92.8% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.54 | 22.7% | 97.2% |
Aktis Oncology Reports Q3 2026 Financial Results and Clinical Trial Progress
12 Nov 2026 · 1d ago, 6:37 pm
Summary
Aktis Oncology reported its third-quarter financial results for the period ended September 30, 2026, alongside significant clinical trial progress. The company's collaboration revenue increased to $3.9 million, up from $1.6 million in the prior year, driven by its research collaboration with Eli Lilly and Company. Operating expenses rose, with R&D expenses at $32.1 million and G&A expenses at $6.5 million, reflecting increased clinical trial activity and headcount. Consequently, the net loss widened to $29.9 million for the quarter. The company ended the quarter with a strong cash position of $492.9 million, which is projected to sustain operations through 2029.
Key Highlights
- 1
Aktis Oncology initiated its third Phase 1b clinical trial, BActinium-2, expanding the evaluation of AKY-2519 to lung cancer and other B7-H3 expressing tumors.
- 2
The company started first backfill cohorts in the ongoing Phase 1b NECTINIUM-2 clinical trial of AKY-1189 and Phase 1b BActinium-1 clinical trial of AKY-2519.
- 3
Collaboration revenue for the third quarter of 2026 was $3.9 million, an increase of $2.3 million compared to the prior-year period.
- 4
Research and development expenses for Q3 2026 were $32.1 million, an increase of $15.6 million driven by clinical trial advancements.
- 5
General and administrative expenses for Q3 2026 were $6.5 million, an increase of $3.2 million due to increased headcount and public company activities.
- 6
Net loss for the third quarter of 2026 was $29.9 million, an increase of $14.4 million compared to the prior-year period, primarily due to higher operating expenses.
- 7
Cash, cash equivalents, and marketable securities stood at $492.9 million as of September 30, 2026, expected to fund operations into 2029.
Management Comments
Matthew Roden
Aktis is on a trajectory to redefine radiopharmaceuticals as a major pillar of cancer treatment by expanding the modality to more targets, broader indications, and larger patient populations. In the third quarter, we continued to make tremendous progress operationalizing this vision. With the initiation of the BActinium-2 trial of AKY-2519, we now have three clinical trials underway in the U.S. across two novel targets, Nectin-4 and B7-H3, which are both implicated in a range of solid tumor types. We also opened the first backfill cohorts in our ongoing NECTINIUM-2 and BActinium-1 trials to further characterize safety and preliminary antitumor activity at the selected doses, while dose escalation continues in both studies. This substantial clinical progress is a testament to our ability to execute rapidly with quality across multiple clinical trials and positions Aktis for a data-rich 2027. With our robust end-to-end supply chain supported by multiple contract manufacturing organizations and isotope suppliers, we are successfully delivering clinical supply for our clinical trials nationally. In the quarter, we operationalized our in-house GMP facility at 17 Drydock in Boston, where we expect to begin supplying drug product for our clinical trials in the first half of 2027, further expanding manufacturing capacity for clinical supply. The 17 Drydock facility progresses our strategy to build capabilities to support potential Phase 3 trials and commercial product supply in a capital-efficient manner.
Informational and educational content only. Not investment advice.